Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chart: Shared Strengths: The Merck And Schering Pipelines

Executive Summary

For a company that takes pride in the strength of its R&D organization, Merck's late-stage pipeline has needed an infusion for some time. High-risk products such as Cordaptive and the CETP inhibitor anaceptrapib have suffered clinical setbacks while drugs like the CB-1 antagonist taranabant have been outright failures, leaving a thin Phase III pipeline ("The Pink Sheet" Oct. 6, 2008, p. 22). The proposed acquisition of Schering-Plough brings Merck some of what it needs - a range of late-stage opportunities that round out the Whitehouse, N.J.-based drugmaker's existing portfolio, strengthening its positions in neuroscience and respiratory drugs. Thanks to Schering, the company will have three pending NME products at FDA this year, where it previously had none. The deal also gives Merck potential blockbuster drugs if TRA and bocepravir deliver in clinical trials. Much of the credit for Schering's pipeline goes to CEO Fred Hassan, who has focused on rebuilding that pharma's pipeline via licensing and acquisition. In particular, the 2007 takeover of Organon BioSciences, which added central nervous system and women's health assets, was critical to Merck's desire to purchase the company. Organon assets now comprise three-quarters of Schering's pipeline. Here's a closer look at the combined Merck-Schering pipeline, with an emphasis on novel products or combinations in mid- to late-stage development.
Advertisement

Related Content

Merck/Schering Merger Brings A Partial Solution For Sales & Marketing
Taranabant Loss No Surprise For Obesity Field, But Shock To Merck’s Pipeline

Topics

Advertisement
UsernamePublicRestriction

Register

PS050806

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel